News for Nektar Therapeutics (0UNL.L)

Published at

Apr 12, 2025 4:55 PM

by gurufocus.com

positive

positive

Nektar Therapeutics (NKTR) Shares Surge on Jefferies Upgrade

Key Takeaways: Nektar Therapeutics (NKTR) shares jump 22% after Jefferies upgrades rating. Analysts project an average target price of $4.92, indicating

NKTR 0UNL.L

Read more →
Published at

Apr 11, 2025 8:29 PM

by gurufocus.com

positive

positive

Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00

Shares of Nektar Therapeutics (NKTR, Financials) rose 26.21% to $0.50 as of 11:36 a.m. ET Friday after Jefferies upgraded the stock from Hold to Buy and increas

NKTR 0UNL.L

Read more →
Published at

Apr 11, 2025 6:56 PM

by gurufocus.com

positive

positive

Nektar Therapeutics (NKTR) Gains After Jefferies Upgrade

Key Highlights: Jefferies upgrades Nektar Therapeutics (NKTR) to "Buy" due to favorable risk-reward dynamics.Anticipation builds for Phase 2b trial results of e

NKTR 0UNL.L

Read more →
Published at

Mar 28, 2025 10:55 PM

by gurufocus.com

positive

positive

Nektar Therapeutics (NKTR) Files $300M Mixed Securities Shelf Offering

Nektar Therapeutics (NKTR) has submitted a filing for a $300 million mixed securities shelf offering. This development comes as the company receives an upgrade

NKTR 0UNL.L

Read more →
Published at

Mar 28, 2025 9:29 PM

by seekingalpha.com

positive

positive

Nektar Therapeutics files $300M mixed securities shelf (NASDAQ:NKTR)

Discover the latest on Nektar Therapeutics (NKTR) as they file a $300M mixed securities shelf.

NKTR 0UNL.L

Read more →
Published at

Mar 22, 2025 11:57 PM

by insidermonkey.com

negative

negative

Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil

We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil.

NKTR 0UNL.L

Read more →
Published at

Mar 14, 2025 2:28 PM

by seekingalpha.com

positive

positive

Nektar stock upgraded at Oppenheimer (NKTR:NASDAQ)

Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read more here.

NKTR 0UNL.L

Read more →
Published at

Mar 14, 2025 12:33 PM

by zacks.com

negative

negative

Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)

Nektar (NKTR) delivered earnings and revenue surprises of -15.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

NKTR 0UNL.L

Read more →
Published at

Mar 13, 2025 8:09 AM

by gurufocus.com

neutral

neutral

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Cash and Investments: $269.1 million at the end of 2024.Revenue: $29.2 million for Q4 2024; $98.4 million for the full year 2024.R&D Expenses: $28.7 million fo

NKTR 0UNL.L

Read more →
Published at

Mar 13, 2025 6:22 AM

by gurufocus.com

positive

positive

Q4 2024 Nektar Therapeutics Earnings Call Transcript

Mar 12, 2025 / 09:00PM GMTOperator Good day and thank you for standing by. Welcome to the Nektar Therapeutics fourth quarter 2024 financial results conference c

NKTR 0UNL.L

Read more →
Published at

Mar 13, 2025 12:00 AM

by zacks.com

neutral

neutral

Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 215.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

NKTR 0UNL.L

Read more →
Published at

Mar 12, 2025 11:00 PM

by gurufocus.com

positive

positive

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

PR NewswireSAN FRANCISCO, March 12, 2025 SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results

NKTR 0UNL.L

Read more →
Published at

Mar 5, 2025 2:00 PM

by gurufocus.com

mixed

mixed

MBX Biosciences Announces Additions to Leadership Team

Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Qualit

ABBV34.SA ABBV.MX ABBV.BA ABBV 4AB.DE NKTR 0UNL.L

Read more →
Published at

Feb 26, 2025 2:00 PM

by gurufocus.com

neutral

neutral

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

PR NewswireSAN FRANCISCO, Feb. 26, 2025 SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has com

NKTR 0UNL.L

Read more →
Published at

Feb 24, 2025 2:00 PM

by gurufocus.com

positive

positive

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

PR NewswireSAN FRANCISCO and NEW YORK, Feb. 24, 2025 -- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study --SAN FRANCISCO and N

NKTR 0UNL.L

Read more →
Published at

Feb 14, 2025 11:13 PM

by gurufocus.com

positive

positive

Samlyn Capital, LLC Increases Stake in Nektar Therapeutics

On December 31, 2024, Samlyn Capital, LLC executed a notable transaction by acquiring an additional 467,097 shares of Nektar Therapeutics at a trade price of $0

NKTR MSFTD.BA MSFTCL.SN MSFTC.BA MSFTB.BA MSFT.MI LPLA FSLR34.SA FSLR.MX FSLR.BA FSLR F3A.DE 0UNL.L 0R06.L

Read more →
Published at

Feb 14, 2025 10:28 PM

by gurufocus.com

positive

positive

Eventide Asset Management, LLC Reduces Stake in Nektar Therapeutics

Eventide Asset Management, LLC, a well-regarded investment firm, recently made a significant adjustment to its holdings in Nektar Therapeutics. On December 31,

ODFL.MX ODFL O1DF34.SA NKTR DHI.MX DHI D1HI34.SA 0UNL.L 0I6K.L 0A7P.L

Read more →
Published at

Feb 14, 2025 5:21 PM

by gurufocus.com

positive

positive

Deep Track Capital, LP Reduces Stake in Nektar Therapeutics

On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) executed a significant transaction involving Nektar Therapeutics (NKTR), reducing its holdings

NKTR ITCI IMVT GH.MX GH APLS 0UNL.L

Read more →
Published at

Feb 10, 2025 2:00 PM

by gurufocus.com

neutral

neutral

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

PR NewswireSAN FRANCISCO, Feb. 10, 2025 SAN FRANCISCO, Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food

NKTR 0UNL.L

Read more →
Published at

Feb 10, 2025 1:32 PM

by rttnews.com

positive

positive

Nektar Therapeutics Gets Fast Track Designation For Rezpegaldesleukin In Atopic Dermatitis; Stock Up

Nektar Therapeutics (NKTR) Monday said that the U.S. Food and Drug Administration or FDA has granted Fast Track designation for its drug candidate rezpegaldesleukin for the treatment of atopic dermatitis in patients aged 12 years and older.

NKTR 0UNL.L

Read more →